Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMAW), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
The Dermata Therapeutics, Inc. (DRMA, DRMAW) news page on Stock Titan aggregates company-issued updates, clinical milestones, financing announcements, and regulatory disclosures related to its dermatology-focused business. Dermata describes itself as a science-driven leader in dermatologic solutions built around its proprietary Spongilla technology platform, with programs in acne, hyperhidrosis, and other skin diseases and aesthetic applications.
Recent news highlights Dermata’s strategic pivot from prescription dermatology development to over-the-counter (OTC) pharmaceutical skin treatments that can be sold directly to consumers. Company press releases and an accompanying Form 8-K explain that Dermata is prioritizing an OTC once-weekly acne kit that combines an active ingredient from the OTC acne monograph with its Spongilla technology, with launch preparations involving branding, packaging, manufacturing, and consumer research.
News items also cover clinical and scientific developments, such as positive topline data from the Phase 3 STAR-1 trial of XYNGARI™ in moderate-to-severe acne, additional data presentations at international dermatology congresses, and collaboration activities around DMT410 for topical botulinum toxin delivery in hyperhidrosis and aesthetic indications. Financing-related releases describe private placements and warrant transactions intended to fund operations and OTC product launch activities, while other notices address Nasdaq listing compliance and corporate actions like a reverse stock split.
Investors and observers can use this news feed to follow Dermata’s progress in OTC dermatology, updates on its Spongilla-based acne kit, developments in its DMT410 program, intellectual property milestones, and material events reported in 8-K filings. Bookmark this page to review Dermata’s historical and ongoing disclosures as it advances its dermatology strategy.
Dermata Therapeutics (NASDAQ:DRMA) has closed a $3.5 million private placement of common stock and warrants priced at-the-market. The offering included 1,912,569 shares (or pre-funded warrants) with accompanying series A and B warrants. Since May 2024, Dermata has raised approximately $7.8 million in gross proceeds, which is expected to fund operations into Q2 2025. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the net proceeds for general corporate purposes, including research, clinical trials, and potential acquisitions. The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their resale in the United States.
Dermata Therapeutics (NASDAQ:DRMA) has announced a $3.5 million private placement priced at-the-market under Nasdaq rules. The offering includes 1,912,569 shares of common stock (or pre-funded warrants) with accompanying series A and B warrants. The purchase price is set at $1.83 per share, with warrants exercisable at $1.58 per share. H.C. Wainwright & Co. is the exclusive placement agent.
The company plans to use the net proceeds for general corporate purposes, including ongoing research, clinical trials, technology development, and potential acquisitions. The closing is expected around September 17, 2024. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their sale in the United States.
Dermata Therapeutics (Nasdaq: DRMA) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The event will be held at the Lotte New York Palace Hotel, with virtual participation options available. Gerry Proehl, Chairman, President, and CEO of Dermata, will present an overview of the company's business and provide an update on their Phase 3 acne program.
The conference will feature over 550 company presentations, available both live and on-demand. Investors interested in attending Dermata's presentation can register through the provided link. The company's virtual presentation will be available on-demand starting September 9 at 7:00 A.M. Eastern Time.
Dermata Therapeutics (Nasdaq: DRMA) has provided a corporate update and reported Q2 2024 financial results. Key highlights include:
1. Over 50% enrollment in DMT310 Phase 3 STAR-1 acne trial
2. Ongoing discussions for DMT410 botulinum toxin partnerships
3. $2.3 million raised in Q2 2024 financing
4. $4.9 million cash on hand as of June 30, 2024
5. R&D expenses increased to $2.0 million in Q2 2024
6. G&A expenses remained stable at $0.9 million
The company expects topline results from STAR-1 in Q1 2025 and anticipates its current cash resources to fund operations into Q4 2024.
Dermata Therapeutics (Nasdaq: DRMA) has announced 50% enrollment in its pivotal Phase 3 STAR-1 clinical trial for DMT310, a novel once-weekly topical treatment for moderate-to-severe acne. The study, which began in December 2023, is the first of two Phase 3 trials aimed at supporting a new drug application (NDA) for DMT310. Topline results are expected in Q1 2025.
The STAR-1 trial is a randomized, double-blind, placebo-controlled study enrolling approximately 550 patients aged 9 and older in the U.S. and Latin America. Primary endpoints include changes in lesion counts and Investigator Global Assessment scores. If approved, DMT310 could become the first once-weekly topical acne treatment, potentially addressing a significant market with about 30 million U.S. acne patients seeking treatment annually.
Dermata Therapeutics announced the exercise of warrants, resulting in approximately $2.66 million in gross proceeds. The warrants were priced at $5.16 per share, a reduction from their original prices of $9.7665 and $32.40. This transaction involved a total of 516,336 shares of the company's common stock. The closing of this offering is expected around May 21, 2024, pending customary conditions.
In exchange, Dermata will issue new Series A and Series B warrants, exercisable immediately and with different terms. Series A warrants cover 601,174 shares, priced at $4.91 per share, and have a term of five and a half years. Series B warrants cover 431,498 shares, with a two-year term.
The proceeds will fund general corporate purposes including ongoing research, clinical trials, and potential acquisitions. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering.
Dermata Therapeutics (Nasdaq: DRMA) reported its first quarter 2024 financial results and provided a corporate update. The company is on track with its DMT310 Phase 3 STAR-1 clinical trial for acne, aiming to complete enrollment by end of 2024 with topline data expected in Q1 2025. Dermata is also in discussions for partnerships for its botulinum toxin delivery program, DMT410, and has received a Japanese patent for treating hyperhidrosis. Financially, Dermata ended Q1 2024 with $4.7 million in cash, down from $7.4 million at the end of 2023, following a $3.1 million net loss. Expenses for R&D and G&A increased due to higher clinical trial and stock-based compensation costs.
Summary not available.
Summary not available.
Summary not available.